• Publications
  • Influence
Patient Preferences for First-Line Oral Treatment for Mild-to-Moderate Ulcerative Colitis
TLDR
Findings indicate that self-reported adherers to UC therapy have a stronger preference for clinical benefits over other treatment attributes, suggesting that positive patient assessment of effectiveness may influence adherence. Expand
Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial
TLDR
The likelihood of remaining in/achieving complete remission at Month 12 was higher for patients who entered the maintenance phase in complete remission compared with those who began maintenance in partial remission, as well as patients achieving complete remission before dose reduction. Expand
Strategies in maintenance for patients receiving long‐term therapy (SIMPLE): A study of MMX mesalamine for the long‐term maintenance of quiescent ulcerative colitis*
TLDR
Conclusions: MMX mesalamine 2.4 g/day QD is effective for maintaining quiescence in patients with UC and adherence to prescribed treatment yielded lower rates of clinical recurrence. Expand
Twelve-Month Persistency with Oral 5-Aminosalicylic Acid Therapy for Ulcerative Colitis: Results from a Large Pharmacy Prescriptions Database
TLDR
Overall persistency with oral 5-ASA therapy was low, however, patients receiving once-daily Lialda had significantly higher persistency after 1 year of treatment than patients receiving other oral 4-aminosalicylic acid therapies. Expand
Diverticular disease in Scotland: 2000–2010
TLDR
Hospital admission rates and management for DD in Scotland between 2000 and 2010 is described to show an increase in incidence in younger age groups. Expand
Factors affecting satisfaction with treatment in European women with chronic constipation: An internet survey
TLDR
Dissatisfied respondents visited their GP less frequently in the past 12 months, were more likely to obtain over-the-counter laxatives, and took a dose higher than recommended more frequently than those satisfied. Expand
The impact of MMX mesalazine on disease‐specific health‐related quality of life in ulcerative colitis patients
TLDR
Past studies with ulcerative colitis patients indicate that disease activity strongly predicts health‐related quality of life (HRQL) and this work aims to extend this finding to patients with UC. Expand
Impact of MMX® Mesalamine on Improvement and Maintenance of Health-Related Quality of Life in Patients with Ulcerative Colitis
TLDR
The sizeable burden of active mild-to-moderate UC on HRQoL was eliminated following 8 weeks' treatment with MMX mesalamine 2.4–4.8 g/day and remained stable over 12 months of maintenance treatment in patients with quiescent UC. Expand
...
1
2
3
4
5
...